what was the first crypto Reviews

The application direction of AI fell in early trading, with Jincai Internet falling more than 8%, followed by Tianyu Digital, Huayang Lianzhong, Fushi Holdings, Aofei Entertainment and Fengyuzhu.The central parity of RMB against the US dollar was reported at 7.1876, down by 22 points; The median price of the previous trading day was 7.1854, the official closing price of the previous trading day was 7.2630, and it closed at 7.2700 last night.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.

Shenzhen accelerates to build a new generation of world-class automobile cities. The total output of automobiles this year is expected to exceed 2.8 million. Over the past hundred years, many well-known "automobile cities" have emerged continuously in the world automobile industry. As one of the earliest cities to develop new energy industry, Shenzhen has a solid foundation for industrial development, actively seizing the historical opportunity of global automobile industry reform and achieving "overtaking in corners" on new energy automobile tracks. In 2023, the output of new energy vehicles in the city reached 1.733 million, ranking first among cities in China. With the acceleration of intelligent process and the high coordination of industrial chain, a "new generation world-class automobile city" is accelerating in Shenzhen. (Shenzhen Special Zone Daily)The growth enterprise market index fell to 1%, the Shanghai Composite Index fell by 0.65% and the Shenzhen Composite Index fell by 0.93%. Securities, real estate and food consumption were among the top losers, with nearly 4,300 stocks falling in Shanghai, Shenzhen and Beijing.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)

Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.Shenzhen started the construction of the first batch of "AI+" medical equipment professional parks. At the 2024 Shenzhen International High Performance Medical Equipment Exhibition and Innovative Medicine Exhibition held on December 12, a number of breakthrough cutting-edge technological achievements and innovative products were unveiled, and more than 200 famous medical equipment enterprises, scientific research institutions and medical institutions from home and abroad gathered to discuss cutting-edge technologies, explore innovative paths of medical equipment and help the high-quality development of the industry. In order to further seize the opportunity of artificial intelligence medical development, accelerate the digital transformation of Shenzhen's biomedical industry, gather a number of characteristic "AI+" medical equipment enterprises, and incubate a number of innovative medical equipment projects, Shenzhen started to build "AI+" medical equipment professional parks in key areas of industrial development. At this exhibition, the construction of the first batch of Shenzhen "AI+" pharmaceutical machinery professional parks, such as Baolong Biomedical Innovation and Development Pilot Zone, Nanshan Zhicheng, Hetao AI+ Biological Professional Park and Yinxing Science and Technology Park, was officially launched. Next, Shenzhen will vigorously improve the development and incubation of new quality productivity in the field of medical equipment, work together to shape the deep integration ecological pattern of "artificial intelligence+medical equipment", and accelerate the development and growth of "AI+" medical equipment industry.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)